// App-Quantinova.ai

PB0845 : Differences in the Prediction of the Time above Target in Hemophilia A Patients Using a Chromogenic Assay and a One-stage Assay in Model-informed Precision Dosing

Researchers

Presenter

  • D.W. Uster

Principal Investigators

  • C.D. Garcia

  • A. Riddell

  • E. Aradom

  • M. Musarara

  • C. Hamid

  • C. Tait

  • S. Mangles

  • N. Curry

  • P. Chowdary

  • S.G. Wicha

Medical Centers

  • University of Hamburg, Institute of Pharmacy, Hamburg, Germany

  • Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust, London, United Kingdom

  • Haemophilia and Thrombosis Centre, Royal Infirmary, Glasgow, United Kingdom

  • Haemophilia, Haemostasis and Thrombosis Centre, Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom

  • Oxford Haemophilia and Thrombosis Centre, Oxford University Hospitals NHS Foundation Trust

Locations

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • Activated partial thromboplastin time

Drug/Treatment

  • FVIII

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved